Low-dose inhaled and nasal corticosteroid use and the risk of cataracts

Orally inhaled corticosteroid use has been convincingly linked to an increase in the risk of cataracts, although the risk at lower doses in common use remains uncertain. The potential risk of cataracts with the use of nasal corticosteroids is unknown. A matched nested case–control analysis was performed in a population-based cohort of elderly people who had been dispensed medications for airway disease, as identified through a universal drug benefit plan. Inhaled corticosteroid use was associated with a dose-related increase in both the risk of all cataracts and severe cataracts requiring extraction, and the increase in risk of severe cataracts was apparent even at daily doses of ≤500 μg. An excess risk with nasal corticosteroids was not apparent for severe cataracts. It is concluded that, among the elderly, even low doses of inhaled corticosteroids are associated with a small but significant excess risk of cataracts requiring extraction. Such an excess risk was not observed with nasal corticosteroids.

[1]  H. Bisgaard,et al.  Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial , 2003, BMJ : British Medical Journal.

[2]  J. Bourbeau,et al.  Inhaled corticosteroids and hospitalisation due to exacerbation of COPD , 2003, European Respiratory Journal.

[3]  C. Acerini,et al.  Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom , 2002, Archives of disease in childhood.

[4]  Brigit VanGraafeiland,et al.  National Asthma Education and Prevention Program. , 2002, The Nurse practitioner.

[5]  M. Zacharisen,et al.  National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002. , 2002, The Journal of allergy and clinical immunology.

[6]  R. Pauwels,et al.  Long-acting inhaled β2-agonist therapy in asthma , 2001 .

[7]  N. Congdon Prevention strategies for age related cataract: present limitations and future possibilities , 2001, The British journal of ophthalmology.

[8]  S. Jick,et al.  The Risk of Cataract among Users of Inhaled Steroids , 2001, Epidemiology.

[9]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[10]  B. Lipworth Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. , 1999, Archives of internal medicine.

[11]  S. Suissa,et al.  Exposure to allopurinol and the risk of cataract extraction in elderly patients. , 1998, Archives of ophthalmology.

[12]  S. Suissa,et al.  Association of inhaled corticosteroid use with cataract extraction in elderly patients. , 1998, JAMA.

[13]  R. Cumming,et al.  Use of inhaled corticosteroids and the risk of cataracts. , 1997, The New England journal of medicine.

[14]  R. Tamblyn,et al.  The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.

[15]  W. Satariano,et al.  Risk factors for age-related cataracts. , 1995, Epidemiologic reviews.

[16]  Alfred O. Berg,et al.  Clinical Guidelines And Primary Care Guidelines For The Diagnosis And Management Of Asthma , 2012 .

[17]  O. Miettinen,et al.  Estimability and estimation in case-referent studies. , 1976, American journal of epidemiology.